Last updated on February 2020

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients


Brief description of study

The purpose of this study is to investigate the safety, pharmacokinetics and preliminary efficacy of combinations treatment of ruxolitinib with 3 novel compounds: siremadlin, crizanlizumab and MBG453 in myelofibrosis (MF) subjects.

Clinical Study Identifier: NCT04097821

Find a site near you

Start Over

Novartis Investigative Site

Melbourne, Australia
6.74miles
  Connect »